Tyre Charley Cowan, Quan Walter
Pitt County Memorial Hospital, Greenville, NC, USA.
Clin J Oncol Nurs. 2007 Aug;11(4):513-9. doi: 10.1188/07.CJON.513-519.
High-dose, continuous-infusion interleukin-2 (IL-2) followed by pulse dose and concurrent administration of famotidine has demonstrated response rates of 64% and 33% in patients with metastatic melanoma and metastatic renal cell carcinoma, respectively. Currently, no information is available concerning the nursing care of patients receiving that IL-2 regimen. Given the high response rates of patients on the treatment, attention by the nursing profession is warranted. Effective nursing care of patients receiving IL-2 is essential to the regimen's success. Recognition and prompt treatment of common side effects lead to better patient outcomes. This article provides nurses with an overview of the treatment regimen, expected side effects, psycho-social considerations, and discharge instructions for patients receiving continuous-infusion plus pulse IL-2 and famotidine.
大剂量持续输注白细胞介素-2（IL-2），随后脉冲给药并同时给予法莫替丁，已证明转移性黑色素瘤患者和转移性肾细胞癌患者的缓解率分别为64%和33%。目前，关于接受该IL-2治疗方案患者的护理尚无相关信息。鉴于接受该治疗的患者缓解率较高，护理专业应予以关注。对接受IL-2治疗的患者进行有效的护理对于该治疗方案的成功至关重要。识别并及时治疗常见副作用可带来更好的患者预后。本文为护士提供了接受持续输注加脉冲IL-2和法莫替丁治疗患者的治疗方案概述、预期副作用、心理社会考虑因素及出院指导。
